. The first evaluation done 0.0 months after the initiation of atezolizumab revealed a rapid progression of liver masses as well as new liver metastasis (000% increase from baseline imaging). Patient subsequently received liver interventional therapy and died 0.0 months from the initiation of atezolizumab. **